

## BioHarvest Sciences Announces Conversion of Debt Notes

**Vancouver, British Columbia and Rehovot, Israel – April 3, 2024** – [BioHarvest Sciences Inc.](#) (“BioHarvest” or the “Company”) (CSE: BHSC) (OTCQB: CNVCF), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced an early conversion of convertible debt notes, associated with the convertible debt financing rounds completed on October 2022, November 2022, July 2023, October 2023 and December 2023.

BioHarvest reports that a total of **CAD \$16,742,435.22** (principal loans plus accrued interest) has been converted into 73,268,708 common shares. As part of the term of 2023 convertible loans, the Company issued 39,775,554 “Early Exercise” warrants at CAD \$0.3 for early conversion. 34,563,008 “Early Exercise” warrants will expire on October 30, 2025, and 5,212,546 will expire on December 22, 2025.

### Terms of the Convertible Notes:

For the terms of the convertible notes, please refer to the following press releases:

1. October & November 2022  
<https://webfiles.thecse.com/221013-NR.pdf?1y9JdR3UUAU4t3r6XO61bhCizjhGvHfye>
2. July 2023  
<https://webfiles.thecse.com/173903.pdf?7O8gUZV1IKwl0ol0bX1yCoo8wNfay6wb>
3. October 2023  
<https://webfiles.thecse.com/185588.pdf?TQ8qRYS5GnE3RGBKFAGuz.L3Ob54phJs>
4. December 2023  
<https://webfiles.thecse.com/192422.pdf?c5rmqUZwELcsf0SPeBlyFWtCt3xUI00q>

### About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based molecules, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit [www.bioharvest.com](http://www.bioharvest.com).

### Forward-Looking Statements

*Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.*

*Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.*

*This release has been reviewed and approved by Dave Ryan, VP Investor Relations, who accepts responsibilities for its contents.*

**BioHarvest Corporate Contact:**

Dave Ryan, VP Investor Relations & Director

+1 (604) 622-1186

[info@bioharvest.com](mailto:info@bioharvest.com)

**Investor Relations Contact:**

Lucas A. Zimmerman

Managing Director

MZ Group - MZ North America

+1 (949) 259-4987

[BHSC@mzgroup.us](mailto:BHSC@mzgroup.us)